Last updated: May 14, 2026
Duramorph PF is a morphine sulfate injection product for opioid analgesia, formulated for parenteral use. No complete, verifiable dataset is available here to produce a clinical-trials update, current market sizing, or an exclusivity-to-revenue projection tied to specific Duramorph PF NDCs, sponsors, trial identifiers, and corresponding Orange Book or patent-expiration milestones.
What is Duramorph PF and who currently markets it?
Featured snippet: Duramorph PF is morphine sulfate injection in a preservative-free format for opioid pain management.
What dosage forms and routes does Duramorph PF cover?
- Active ingredient: morphine sulfate
- Form: injection
- Presentation: preservative-free (PF)
- Routes: parenteral (typical for morphine injection programs)
How does Duramorph PF fit into the opioid analgesic landscape?
- Competitive set typically includes other injectable morphine sulfate strengths/formats and opioid analgesics used perioperatively and for acute pain.
What clinical trials have been run for Duramorph PF, and what is the latest status?
Featured snippet: A Duramorph PF-specific trials timeline cannot be produced from the information available in this session.
Which registries should define the latest update?
- ClinicalTrials.gov entries for:
- Duramorph PF-specific NCT identifiers
- sponsor and study completion dates
- ongoing status and results posting
What endpoints drive an investor-grade “update”?
- Safety outcomes: respiratory depression, sedation, hemodynamics
- Efficacy endpoints: pain scores (e.g., VAS/NRS), time to analgesia
- Product-specific endpoints: injection tolerability and preservative-free comparability where studied
How does Duramorph PF compare with other injectable morphine sulfate products?
Featured snippet: The primary differentiation is typically formulation and presentation (preservative-free vs multi-dose preparations), not a distinct active ingredient.
What are the main competitive axes?
- Preservative-free formulation availability
- Packaging and dose presentation
- Strength coverage and institutional pull-through
- Labeling nuances for route and indication scope
Where do substitution and switching risk concentrate?
- Hospitals and ambulatory surgery settings switch based on:
- formulary placement
- supply reliability
- procurement pricing
- nursing administration requirements (multi-dose vs single-dose formats)
What patents protect Duramorph PF, and when do they expire?
Featured snippet: A Duramorph PF-specific patent list and expiration schedule cannot be generated without Orange Book and patent-number mappings to the relevant NDC(s).
Which IP buckets usually matter for injectable opioids?
- Composition of matter (API salt and/or formulation)
- Methods of treatment (if tied to specific dosing regimens or indications)
- Formulation patents (preservative-free composition, pH control, excipients)
- Manufacturing process patents
- Orange Book-listed exclusivities that can block generic substitution
How to translate patent schedules into exclusivity-to-launch windows
- Patent expiry date by claim set
- Orange Book exclusivity end dates (e.g., 5/7/10-year exclusivity where applicable)
- Practical launch blockers: patent-by-patent litigation and NDA-holder market exclusivity behavior
What is the Orange Book status of Duramorph PF?
Featured snippet: Orange Book status and listed patents by NDC cannot be reported from the information available here.
What to extract for a clean regulatory/IP picture
- Listed patents and regulatory exclusivities by NDC
- “Type” of patent (drug substance, drug product, method)
- Patent expiry dates
- Any ongoing or completed Paragraph IV narrative if listed
What Paragraph IV challenges or generic entry risks exist for Duramorph PF?
Featured snippet: Paragraph IV litigation and/or ANDA filings cannot be confirmed without an Orange Book and litigation docket dataset tied to Duramorph PF NDCs.
What to look for in an ANDA risk assessment
- ANDA filer and approval status
- Paragraph IV grounds and asserted patents
- Settlement terms if a consent decree is disclosed
- Country-specific risk if distribution extends beyond the US
How strong is the patent estate for Duramorph PF?
Featured snippet: Patent strength scoring for Duramorph PF cannot be computed without the underlying patent family, claim scope, remaining term, and litigation posture.
What signals typically drive strength scores in injectable opioids
- Number of unexpired listed patents
- Breadth of claim coverage across:
- formulation and preservative-free composition
- dosing/regimen method claims
- manufacturing or control strategy claims
- Litigation outcomes and validity rulings
How will Duramorph PF revenue likely evolve under exclusivity and generic pressure?
Featured snippet: Revenue projection requires NDC-level market data and a patent-to-approval timeline; those inputs are not available here.
What the model needs for a projection that holds up in investment review
- Current and trailing revenue by:
- NDC-level or equivalent US dispensed market data
- channel mix (hospital, outpatient, government contracts)
- Price erosion assumptions tied to generic entry:
- time-to-first generic penetration
- subsequent competitive intensity (multiple ANDAs)
- hospital formulary switching rate
What a typical injection-opioid post-entry curve looks like
- Rapid unit-share shift once an equivalent generic becomes available
- Margin compression driven by acquisition and tender pricing
- Continued brand resilience if:
- supply chain reliability is better
- PF packaging is preferred
- payor or institution contracts lock in usage
What market share and pricing benchmarks apply to Duramorph PF?
Featured snippet: No market-share, pricing, or benchmark dataset is available in this session.
Key benchmarks to tie to a forecast
- US opioid analgesic injection dispensed volume trends
- Brand-to-generic price indexes by therapeutic equivalence
- PF-specific procurement dynamics and substitution behavior
Key takeaways
- A Duramorph PF clinical-trials update, Orange Book status, patent expiration schedule, Paragraph IV risk assessment, and exclusivity-to-revenue projection cannot be produced from the information available in this session.
- Delivering a business-usable forecast requires NDC-level linkage to:
- FDA regulatory status
- Orange Book listed patents and exclusivities
- any ANDA/Paragraph IV and litigation outcomes
- trial registration records tied to the product
FAQs
- How can I find Duramorph PF’s FDA NDC-level Orange Book listings?
- What is the difference between Duramorph PF and other morphine sulfate injection products (PF vs non-PF)?
- Do preservative-free injectable opioids face different generic substitution rules than non-PF forms?
- When do opioid injection brands typically lose exclusivity relative to ANDA approval timing?
- What endpoints in injectable opioid trials determine label expansions or dosing changes?
References
No sources were used in this response.
